Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Loehrer PJ, S.
Right arrow Articles by Einhorn, L. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Loehrer PJ, S.
Right arrow Articles by Einhorn, L. H.

Journal of Clinical Oncology, Vol 16, 2500-2504, Copyright © 1998 by American Society of Clinical Oncology

ARTICLES

Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor

Sr Loehrer PJ, R Gonin, CR Nichols, T Weathers and LH Einhorn
Indiana University Medical Center, Indianapolis, USA. patrick_loehrer@iupui.edu

PURPOSE: This study was designed to assess the effectiveness of vinblastine, ifosfamide, and cisplatin (VeIP) as second-line therapy in patients with recurrent germ cell tumors with previous treatment with cisplatin plus etoposide, usually in combination with bleomycin. PATIENTS AND METHODS: From July 1984 through December 1989, 135 patients with progressive, disseminated germ cell tumors after cisplatin-etoposide-based combination therapy induction chemotherapy were treated with VeIP. Patients who progressed within 3 weeks of previous cisplatin therapy were not eligible. Progression was documented by biopsy or increasing serum markers. No exclusion was made on the basis of metastatic site or performance status. The dosages were vinblastine 0.11 mg/kg/d (days 1 and 2), ifosfamide 1.2 gm/m2/d (days 1 through 5), and cisplatin 20 mg/m2/d (days 1 through 5), with courses repeated every 21 days for four cycles. RESULTS: Sixty-seven (49.6%) patients achieved a disease-free status after chemotherapy with or without surgical resection of residual carcinoma or teratoma. Overall, 42 (32%) patients are alive and 32 (23.7%) are continuously free of disease. None of the 32 patients with nonseminomatous extragonadal tumors are disease-free compared with 30 of 100 patients with gonadal primaries. Two of three extragonadal seminomas are continuously disease- free. CONCLUSION: VeIP is capable of producing durable complete remissions in patients with disseminated germ cell cancer who relapse after cisplatin-etoposide-based induction therapy. Long-term disease- free survival is not seen in those patients with extragonadal nonseminomatous germ cell tumors.


This article has been cited by other articles:


Home page
 JAMAHome page
D. R. Feldman, G. J. Bosl, J. Sheinfeld, and R. J. Motzer
Medical Treatment of Advanced Testicular Cancer
JAMA, February 13, 2008; 299(6): 672 - 684.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
K. A. Kesler, K. M. Rieger, Z. T. Hammoud, L. E. Kruter, S. M. Perkins, M. W. Turrentine, B. P. Schneider, L. H. Einhorn, and J. W. Brown
A 25-Year Single Institution Experience With Surgery for Primary Mediastinal Nonseminomatous Germ Cell Tumors
Ann. Thorac. Surg., February 1, 2008; 85(2): 371 - 378.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. J. Stephenson, G. J. Bosl, R. J. Motzer, D. F. Bajorin, J. P. Stasi, and J. Sheinfeld
Nonrandomized Comparison of Primary Chemotherapy and Retroperitoneal Lymph Node Dissection for Clinical Stage IIA and IIB Nonseminomatous Germ Cell Testicular Cancer
J. Clin. Oncol., December 10, 2007; 25(35): 5597 - 5602.
[Abstract] [Full Text] [PDF]

Home page
 Postgrad. Med. J.Home page
O. Khan and A. Protheroe
Testis cancer
Postgrad. Med. J., October 1, 2007; 83(984): 624 - 632.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
L. H. Einhorn, S. D. Williams, A. Chamness, M. J. Brames, S. M. Perkins, and R. Abonour
High-Dose Chemotherapy and Stem-Cell Rescue for Metastatic Germ-Cell Tumors
N. Engl. J. Med., July 26, 2007; 357(4): 340 - 348.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. M. Gershenson
Management of Ovarian Germ Cell Tumors
J. Clin. Oncol., July 10, 2007; 25(20): 2938 - 2943.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Lorch, C. Kollmannsberger, J. T. Hartmann, B. Metzner, I. G.H. Schmidt-Wolf, W. E. Berdel, F. Weissinger, J. Schleicher, G. Egerer, A. Haas, et al.
Single Versus Sequential High-Dose Chemotherapy in Patients With Relapsed or Refractory Germ Cell Tumors: A Prospective Randomized Multicenter Trial of the German Testicular Cancer Study Group
J. Clin. Oncol., July 1, 2007; 25(19): 2778 - 2784.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J Shamash, T Powles, K Mutsvangwa, P Wilson, W Ansell, E Walsh, D Berney, J Stebbing, and T Oliver
A phase II study using a topoisomerase I-based approach in patients with multiply relapsed germ-cell tumours
Ann. Onc., May 1, 2007; 18(5): 925 - 930.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. H. Einhorn, M. J. Brames, B. Juliar, and S. D. Williams
Phase II Study of Paclitaxel Plus Gemcitabine Salvage Chemotherapy for Germ Cell Tumors After Progression Following High-Dose Chemotherapy With Tandem Transplant
J. Clin. Oncol., February 10, 2007; 25(5): 513 - 516.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
G. Sonpavde, T. E. Hutson, and B. J. Roth
Management of Recurrent Testicular Germ Cell Tumors
Oncologist, January 1, 2007; 12(1): 51 - 61.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. V. Kondagunta and R. J. Motzer
Chemotherapy for Advanced Germ Cell Tumors
J. Clin. Oncol., December 10, 2006; 24(35): 5493 - 5502.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Oldenburg, J. M. Martin, and S. D. Fossa
Late Relapses of Germ Cell Malignancies: Incidence, Management, and Prognosis
J. Clin. Oncol., December 10, 2006; 24(35): 5503 - 5511.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. M. Bedano, M. J. Brames, S. D. Williams, B. E. Juliar, and L. H. Einhorn
Phase II Study of Cisplatin Plus Epirubicin Salvage Chemotherapy in Refractory Germ Cell Tumors
J. Clin. Oncol., December 1, 2006; 24(34): 5403 - 5407.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
K. Kawai, S. Hinotsu, T. Oikawa, N. Sekido, K. Hattori, N. Miyanaga, Y. Hasegawa, H. Kojima, T. Shimazui, and H. Akaza
Treatment Outcome of Metastatic Testicular Cancer at a Single Institution in Japan, a Country with Low Incidence of Germ Cell Tumor
Jpn. J. Clin. Oncol., November 1, 2006; 36(11): 723 - 730.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. A. Ronnen, G. V. Kondagunta, J. Bacik, S. Marion, D. F. Bajorin, J. Sheinfeld, G. J. Bosl, and R. J. Motzer
Incidence of Late-Relapse Germ Cell Tumor and Outcome to Salvage Chemotherapy
J. Clin. Oncol., October 1, 2005; 23(28): 6999 - 7004.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. V. Kondagunta, J. Bacik, A. Donadio, D. Bajorin, S. Marion, J. Sheinfeld, G. J. Bosl, and R. J. Motzer
Combination of Paclitaxel, Ifosfamide, and Cisplatin Is an Effective Second-Line Therapy for Patients With Relapsed Testicular Germ Cell Tumors
J. Clin. Oncol., September 20, 2005; 23(27): 6549 - 6555.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J.-P. Lotz, B. Bui, F. Gomez, C. Theodore, A. Caty, K. Fizazi, G. Gravis, R. Delva, J. Peny, P. Viens, et al.
Sequential high-dose chemotherapy protocol for relapsed poor prognosis germ cell tumors combining two mobilization and cytoreductive treatments followed by three high-dose chemotherapy regimens supported by autologous stem cell transplantation. Results of the phase II multicentric TAXIF trial
Ann. Onc., March 1, 2005; 16(3): 411 - 418.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
U. De Giorgi, T. Demirer, H. Wandt, C. Taverna, W. Siegert, M. Bornhauser, T. Kozak, G. Papiani, M. Ballardini, G. Rosti, et al.
Second-line high-dose chemotherapy in patients with mediastinal and retroperitoneal primary non-seminomatous germ cell tumors: the EBMT experience
Ann. Onc., January 1, 2005; 16(1): 146 - 151.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
H. J. Schmoll, R. Souchon, S. Krege, P. Albers, J. Beyer, C. Kollmannsberger, S. D. Fossa, N. E. Skakkebaek, R. de Wit, K. Fizazi, et al.
European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG)
Ann. Onc., September 1, 2004; 15(9): 1377 - 1399.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
W. Houck, R. Abonour, G. Vance, and L. H. Einhorn
Secondary Leukemias in Refractory Germ Cell Tumor Patients Undergoing Autologous Stem-Cell Transplantation Using High-Dose Etoposide
J. Clin. Oncol., June 1, 2004; 22(11): 2155 - 2158.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. J. Motzer and J. Sheinfeld
Poor-Risk Testicular Cancer and High-Dose Chemotherapy
J. Clin. Oncol., November 15, 2003; 21(22): 4073 - 4074.
[Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
K. Kawai, J. Miyazaki, S. Tsukamoto, S. Hinotsu, K. Hattori, T. Shimazui, and H. Akaza
Paclitaxel, Ifosfamide and Cisplatin Regimen is Feasible for Japanese Patients with Advanced Germ Cell Cancer
Jpn. J. Clin. Oncol., March 1, 2003; 33(3): 127 - 131.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. W. George, R. S. Foster, R. A. Hromas, K. A. Robertson, G. H. Vance, T. M. Ulbright, T. A. Gobbett, D. J. Heiber, N. A. Heerema, H. C. Ramsey, et al.
Update on Late Relapse of Germ Cell Tumor: A Clinical and Molecular Analysis
J. Clin. Oncol., January 1, 2003; 21(1): 113 - 122.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. A. Gietema, M. T. Meinardi, D. T. Sleijfer, H. J. Hoekstra, and W. T. A. van der Graaf
Routine chest X-rays have no additional value in the detection of relapse during routine follow-up of patients treated with chemotherapy for disseminated non-seminomatous testicular cancer
Ann. Onc., October 1, 2002; 13(10): 1616 - 1620.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
L. H. Einhorn
Inaugural Article: Curing metastatic testicular cancer
PNAS, April 2, 2002; 99(7): 4592 - 4595.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Hinton, P. Catalano, L. H. Einhorn, P. J. Loehrer Sr, T. Kuzel, D. Vaughn, and G. Wilding
Phase II Study of Paclitaxel Plus Gemcitabine in Refractory Germ Cell Tumors (E9897): A Trial of the Eastern Cooperative Oncology Group
J. Clin. Oncol., April 1, 2002; 20(7): 1859 - 1863.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. Bokemeyer, C. R. Nichols, J.-P. Droz, H.-J. Schmoll, A. Horwich, A. Gerl, S. D. Fossa, J. Beyer, J. Pont, L. Kanz, et al.
Extragonadal Germ Cell Tumors of the Mediastinum and Retroperitoneum: Results From an International Analysis
J. Clin. Oncol., April 1, 2002; 20(7): 1864 - 1873.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. Beyer, S. Stenning, A. Gerl, S. Fossa, and W. Siegert
High-dose versus conventional-dose chemotherapy as first-salvage treatment in patients with non-seminomatous germ-cell tumors: a matched-pair analysis
Ann. Onc., April 1, 2002; 13(4): 599 - 605.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
K. Fizazi, S. Tjulandin, R. Salvioni, J. R. Germa-Lluch, J. Bouzy, D. Ragan, C. Bokemeyer, A. Gerl, A. Flechon, J. S. de Bono, et al.
Viable Malignant Cells After Primary Chemotherapy for Disseminated Nonseminomatous Germ Cell Tumors: Prognostic Factors and Role of Postsurgery Chemotherapy--Results From an International Study Group
J. Clin. Oncol., May 15, 2001; 19(10): 2647 - 2657.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. T. Hartmann, L. Einhorn, C. R. Nichols, J.-P. Droz, A. Horwich, A. Gerl, S. D. Fossa, J. Beyer, J. Pont, H.-J. Schmoll, et al.
Second-Line Chemotherapy in Patients With Relapsed Extragonadal Nonseminomatous Germ Cell Tumors: Results of an International Multicenter Analysis
J. Clin. Oncol., March 15, 2001; 19(6): 1641 - 1648.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
O. Rick, C. Bokemeyer, J. Beyer, J. T. Hartmann, N. Schwella, D. Kingreen, S. Neureither, B. Metzner, J. Casper, H. Wandt, et al.
Salvage Treatment With Paclitaxel, Ifosfamide, and Cisplatin Plus High-Dose Carboplatin, Etoposide, and Thiotepa Followed by Autologous Stem-Cell Rescue in Patients With Relapsed or Refractory Germ Cell Cancer
J. Clin. Oncol., January 1, 2001; 19(1): 81 - 88.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Bhatia, R. Abonour, P. Porcu, R. Seshadri, C.R. Nichols, K. Cornetta, and L.H. Einhorn
High-Dose Chemotherapy as Initial Salvage Chemotherapy in Patients With Relapsed Testicular Cancer
J. Clin. Oncol., October 19, 2000; 18(19): 3346 - 3351.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. J. Motzer, J. Sheinfeld, M. Mazumdar, M. Bains, T. Mariani, J. Bacik, D. Bajorin, and G. J. Bosl
Paclitaxel, Ifosfamide, and Cisplatin Second-Line Therapy for Patients With Relapsed Testicular Germ Cell Cancer
J. Clin. Oncol., June 12, 2000; 18(12): 2413 - 2418.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. J. Motzer, M. Mazumdar, J. Sheinfeld, D. F. Bajorin, H. A. Macapinlac, M. Bains, L. Reich, C. Flombaum, T. Mariani, W. P. Tong, et al.
Sequential Dose-Intensive Paclitaxel, Ifosfamide, Carboplatin, and Etoposide Salvage Therapy for Germ Cell Tumor Patients
J. Clin. Oncol., March 13, 2000; 18(6): 1173 - 1180.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. H. Einhorn, M. J. Stender, and S. D. Williams
Phase II Trial of Gemcitabine in Refractory Germ Cell Tumors
J. Clin. Oncol., February 1, 1999; 17(2): 509 - 509.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
L. H. Einhorn
Inaugural Article: Curing metastatic testicular cancer
PNAS, April 2, 2002; 99(7): 4592 - 4595.
[Abstract] [Full Text] [PDF]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 1998 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online